An observational study in STEMI, Coronary Artery Disease and Coronary Syndrome, sponsored by University of Campania Luigi Vanvitelli. Completed at 1 site in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-10-19.
Sponsored by University of Campania Luigi Vanvitelli · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in ST Elevation Myocardial Infarction with a site in Italy — 13 open to participants now, 17 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · Italy.
Among the 70 studies in ST Elevation Myocardial Infarction with a site in Italy, this one is the 10th largest by enrollment of the 29 observational ones that give a count, is one of 3 that started in 2017, is one of 29 observational ones, and was the 36th registered.
851 studies on the registry are indexed under ST Elevation Myocardial Infarction; 198 are open to participants now.
Browse ST Elevation Myocardial Infarction studies →13 of the 70 studies in ST Elevation Myocardial Infarction with a site in Italy are open now. Recruiting first, the newest first:
Ceric Sàrl · Sites in Italy
Ages 18–75
Federico II University · Sites in Italy
Ages 18–80
Azienda Ospedaliera "Sant'Andrea" · Sites in Italy
Ages 18+
University of Pisa · Sites in Italy
Healthy volunteers
Heart Care Foundation · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 122 ST Elevation Myocardial Infarction studies recruiting now, 76 (62%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 10 · Phase 4 14
First in 2003; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 900 is above the median of 335 across 297 observational studies indexed under ST Elevation Myocardial Infarction.
Median enrollment 148 across the 41 interventional studies, 350 across the 29 observational. Of the 31 that completed or were terminated, 7 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 70 have an industry lead sponsor. The 10 most frequent:
University of Campania Luigi Vanvitelli is the lead sponsor of 174 studies on the registry; 28 are open to participants now.
University of Campania Luigi Vanvitelli has 2 studies filed under ST Elevation Myocardial Infarction — fewer than ten, so there is no comparison to draw.
6 of the studies in ST Elevation Myocardial Infarction with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06965023Azienda Ospedaliera "Sant'Andrea"Microplastics and Nanoplastics (MNPs) in Patients With ST-elevation Myocardial Infarction (STEMI) | 2026-12-30 |
| NCT06887413Ceric SàrlTACTIC Coronary Thrombus Aspiration With Cath Rx In Anterior Myocardial Infarction: A Randomized Control Trial. | 2027-02-28 |
| NCT07176104Raffaele MarfellaFunctional Milk Supplementation to Reduce In-Stent Restenosis in STEMI Patients (SMASOEA Trial) | 2027-06 |
| NCT07598565University of Roma La SapienzaThe CORE - μFR Clinical Trial | 2027-06-25 |
| NCT05491200Research Maatschap Cardiologen Rotterdam ZuidComparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients | 2027-08-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 70 studies in ST Elevation Myocardial Infarction with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
ST elevation myocardial infarction (STEMI) patients affected by multivessels coronary artery stenosis, represent a clinical relevant problem. The management and prognosis of these patents are supported by few literature data. Therefore, in this study authors enrolled real world diabetic vs. non diabetic patients admitted for STEMI and associated to multi vessels coronary disease. Then these diabetics were divided in incretin users (6 months of incretin treatment before study enrollment) vs. never incretin users. In these patients authors studied all cause mortality, cardiac mortality, and major adverse cardiac events at 12 months follow up.
ST elevation myocardial infarction (STEMI) patients affected by multivessels coronary artery stenosis represent a class of patients really challenging to treat. In fact, treatment, clinical management, and prognosis are supported by few literature data. Therefore, in this study authors enrolled real world patients admitted for STEMI and associated to multi vessels coronary disease. Multivessels (Mv) coronary stenosis were characterized by non obstructive coronary stenosis (NOCS) as coronary lesions \<50% with fractional flow reserve > 0.8. Therefore, STEMI was treated by percutaneous coronary intervention by primary angioplasty and direct stenting (DES stenting) of culprit vessel lesion. Then these STEMI-Mv-NOCS patients were divided in diabetics vs. non diabetics, and received conventional full medical therapy for STEMI. Then these diabetics were divided in incretin users (6 months of incretin treatment before study enrollment) vs. never incretin users. Study outcomes were all cause mortality, cardiac mortality, and major adverse cardiac events at 12 months follow up. Authors studied these study outcomes comparing diabetics vs. non diabetics at 12 moths follow up, and diabetics incretin-users vs. never-incretin-users.
Diabetics and non diabetics patients admitted for STEMI. In this population authors selected STEMI patients with multivessel (Mv) non obstructive coronary diseases (NOCS). These STEMI-Mv-NOCS had coronary lesions and stenosis \<50%, with fractional flow reserve >0.8. In diabetics authors selected incretin users (6 months of incretin treatment before study enrollment) vs never-incretin-users diabetics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
aged >18, first STEMI, STEMI with multi vessels coronary stenosis.
Exclusion Criteria:
aged \< 18, renal impairment, mono vessel STEMI, severe depression of left ventricle (LVEF \<35%).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy.
Device: PCI and DES stenting
Non diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis(Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy.
Device: PCI and DES stenting
Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy. These patients were treated by incretin therapy at last 6 months before study enrollment.
Device: PCI and DES stenting · Drug: Incretins
Diabetics patients admitted for ST elevation myocardial infarction (STEMI) and associated with multi vessels coronary artery stenosis (Mv) non obstructive coronary artery stenosis (NOCS). These patients received percutaneous coronary intervention (PCI), and primary stenting (DES) of culprit lesion. Then these patients received full medical STEMI therapy. These diabetic patients were never treated by incretin therapy before study enrollment.
Device: PCI and DES stenting
Percutaneous coronary intervention (PCI) and direct stenting (DES) of culprit lesion vessel.
Patients treated before study enrollment by incretin drugs (6 months drugs exposure)
all cause deaths
at 12 months follow up authors monitored and reported all cause mortality
Time frame: 12 months
cardiac deaths
at 12 months follow up authors monitored and reported mortality events due to cardiac causes
Time frame: 12 months
MACE
authors monitored and reported at follow up major adverse cardiac events (MACE): re-STEMI, NSTEMI, unstable angina, arrhythmias, stroke etc.
Time frame: 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2017 to primary completion in Sep 2017, 8 months.
Of 122 non-industry observational studies under ST Elevation Myocardial Infarction, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 107. This study's 8 months is below that.
Counting every sponsor, half of 143 studies reached it within 38 months; a quarter within 20 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ST Elevation Myocardial Infarction →
University of Campania Luigi Vanvitelli →